ASTEROID Trial

Revision as of 00:36, 18 September 2013 by Rim Halaby (talk | contribs)
Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

ASTEROID Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of ASTEROID Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on ASTEROID Trial

CDC on ASTEROID Trial

ASTEROID Trial in the news

Blogs on ASTEROID Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for ASTEROID Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for ASTEROID Trial.

ASTEROID Trial

Objective

To assess if an extensive lipid lowering therapy with statins could regress coronary atherosclerosis as determined by IVUS imaging.

Methods

A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) was a prospective open-label blinded end-points trial wherein 507 patients, who had a baseline IVUS examination, received at least 1 dose of the study drug rosuvastatin 40 mg/dL and were followed up for 24 months. At the end of 24 months 349 patients had evaluable serial IVUS examinations.

Results

Mean baseline LDL-C reduced by 53.2% and mean HDL-C improved by 14.7%. Also mean atheroma volume for the entire vessel, as assessed by intravascular ultrasound, reduced by 0.98%.

Conclusion

The study showed that treatment with very high intensity statin therapy using rosuvastatin 40 mg/dL reduced LDL-C and improved HDL-C levels significantly resulting in regression of coronary atherosclerosis as measured by IVUS.[1]

References

  1. "Effect of very high-intensity statin therapy on regress... [JAMA. 2006] - PubMed - NCBI".